Navigation Links
NutraCea Announces $20 Million Securities Offering
Date:4/25/2008

-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission, including the company's most recent periodic report.

Company Contact:

Margie Adelman

Senior V.P. NutraCea

602-522-3000

916-220-3500 cell

madelman@nutracea.com


'/>"/>
SOURCE NutraCea
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. NutraCea Appoints Financial Relations Board as New Investor Relations Firm
2. NutraCea to Host Third Quarter 2007 Financial Results Conference Call November 14
3. NutraCea Announces Conference Call to Report Second Quarter Financial Results
4. NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran
5. NutraCea Provides Update on Domestic Operations
6. NutraCea Files Universal Shelf Registration Statement
7. NutraCea to Purchase Largest Rice Bran Oil Processing Facility in South America
8. New World Record Holder in Powerlifting Credits NutraCeas Unique Rice-Bran-derived Product as his Secret Weapon
9. NutraCea Appoints New Chief Financial Officer
10. NutraCea-Sponsored Study Demonstrates Benefits of Replacing Wheat Flour with Stabilized Rice Bran (SRB) in Battered and Fried Product Applications
11. Demand for NutraCea Rice Bran Oil Prompts Major Expansion of Irgovel Plant Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Expanding Patient Population Creates a Huge Market for Invasive Pressure Monitoring and Hemodynamic Monitoring, Finds Frost & Sullivan 2Health News:Expanding Patient Population Creates a Huge Market for Invasive Pressure Monitoring and Hemodynamic Monitoring, Finds Frost & Sullivan 3Health News:Expanding Patient Population Creates a Huge Market for Invasive Pressure Monitoring and Hemodynamic Monitoring, Finds Frost & Sullivan 4Health News:LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees 2Health News:Al Copeland Foundation Signs on as Title Sponsor of 2009 Chris Paul Basketball Camp 2Health News:Al Copeland Foundation Signs on as Title Sponsor of 2009 Chris Paul Basketball Camp 3Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 2Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 3Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 4Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 5Health News:A Star-Filled Evening with The AFA's Illuminations Los Angeles 2Health News:A Star-Filled Evening with The AFA's Illuminations Los Angeles 3Health News:Dr. Rudy Kachmann, Neurosurgeon, Author, Lecturer & Founder of Kachmann Mind Body Institute Selects TransMedia Group as Agency of Record 2
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3HealthFitness Announces Third Quarter 2009 Financial Results 60712 1HealthFitness Announces Third Quarter 2009 Financial Results 60712 2HealthFitness Announces Third Quarter 2009 Financial Results 60712 3HealthFitness Announces Third Quarter 2009 Financial Results 60712 4HealthFitness Announces Third Quarter 2009 Financial Results 60712 5HealthFitness Announces Third Quarter 2009 Financial Results 60712 6HealthFitness Announces Third Quarter 2009 Financial Results 60712 7HealthFitness Announces Third Quarter 2009 Financial Results 60712 8HealthFitness Announces Third Quarter 2009 Financial Results 60712 9HealthFitness Announces Third Quarter 2009 Financial Results 60712 10HealthFitness Announces Third Quarter 2009 Financial Results 60712 11Regence Foundation Announces Largest Set of Quarterly Grant Awards in Its History 60707 1Regence Foundation Announces Largest Set of Quarterly Grant Awards in Its History 60707 2Regence Foundation Announces Largest Set of Quarterly Grant Awards in Its History 60707 3Zyngenia Inc Raises 2410 Million in Series A Funding 14724 1Zyngenia Inc Raises 2410 Million in Series A Funding 14724 2Zyngenia Inc Raises 2410 Million in Series A Funding 14724 3Zyngenia Inc Raises 2410 Million in Series A Funding 14724 4